Biotech2 months ago
GigaGen Signs $135 Million US Contract for Manufacturing and Testing
GigaGen will develop a recombinant polyclonal antibody therapy for botulinum neurotoxins and another biological threat. Grifols expects €930 million in U.S. revenues from Yimmugo, an immunoglobulin...